roossinck
mj
bujarski
mj
ding
sw
et
al
primev
notion
immun
diseas
aros
greec
centuri
ago
observ
recov
appar
contagi
diseas
becam
resist
subsequ
similar
sick
earliest
known
attempt
intent
transfer
immun
infecti
diseas
occur
china
tenth
centuri
involv
expos
uninfect
peopl
materi
lesion
caus
smallpox
alway
success
practic
introduc
seventeenth
centuri
ottoman
empir
subsequ
england
coloni
north
america
approach
revolution
replac
materi
human
lesion
deriv
cowpox
lesion
first
england
farmer
benjamin
jesti
use
famili
year
later
edward
jenner
thereaft
wide
use
vaccin
consid
first
exampl
immun
lifeattenu
viru
nevertheless
caus
diseas
success
vaccin
remain
unexplain
understand
start
emerg
centuri
later
koch
pasteur
set
forth
germ
theori
infecti
diseas
pasteur
develop
attenu
vaccin
anthrax
rabi
von
behr
kitasato
demonstr
immun
could
transfer
solubl
serum
compon
sever
decad
later
compon
shown
antibodi
immunoglobulin
heidelberg
kabat
whose
fundament
structur
elucid
porter
edelman
late
character
numer
xray
crystallographi
sequenc
studi
howev
sever
find
indic
antibodi
mediat
specif
immun
immun
respons
correspond
delay
hypersensit
allograft
reject
appear
unrel
presenc
serum
antibodi
immun
could
also
transfer
cell
immun
naiv
anim
landstein
chase
shown
gowan
colleagu
lymphocyt
essenti
immun
respons
antibodi
mani
distinct
antigen
produc
upon
immun
therefor
presum
divers
antibodi
preform
would
gener
demand
follow
antigen
stimuli
theori
two
possibl
antigen
either
direct
select
format
specif
antibodi
studi
fulli
support
clonal
select
theori
burnet
jern
talmag
repertoir
divers
antibodi
undergo
process
matur
lead
highaffin
antibodi
gener
somat
rearrang
hypermut
immunoglobulin
gene
tonegawa
although
becam
evid
immunoglobulin
cell
essenti
immun
detail
process
wherebi
antigen
virus
elicit
immun
respons
contribut
result
studi
transplant
biolog
notabl
discoveri
major
histocompat
complex
mhc
hla
molecul
human
cell
benaceraff
dausset
snell
role
present
antigen
fragment
interact
specif
antibodi
produc
bcell
tcell
well
function
cytokin
chemokin
adhes
molecul
discuss
later
section
articl
immunoglobulin
lymphocyt
mhc
molecul
antigen
receptor
compon
adapt
acquir
immun
compon
innat
immun
respond
rapidli
invad
pathogen
play
key
role
initi
orchestr
adapt
respons
janeway
major
mileston
histori
immunolog
time
line
summar
tabl
adapt
immun
system
base
clonal
divers
repertoir
antigen
recognit
molecul
aros
jaw
vertebr
gnasthostom
million
year
ago
homolog
human
immunoglobulin
tcell
antigen
receptor
tcr
mhc
mhc
ii
molecul
recombin
activ
gene
rag
identifi
class
gnasthostom
provid
evolutionari
advantag
allow
recognit
potenti
lethal
pathogen
includ
virus
initi
protect
respons
figur
repres
addon
preexist
innat
immun
system
immunoglobulin
somat
variat
expand
class
switch
gene
convers
somat
hypermut
jawless
vertebr
agnathan
shown
also
adapt
immun
system
base
recombinatori
assembl
genet
unit
differ
gnasthostom
gener
divers
repertoir
lymphocyt
distinct
receptor
figur
assembl
reli
highli
variabl
leucinerich
repeat
lrr
protein
modular
unit
gnasthotom
gener
larg
part
immuglobulin
divers
way
similar
human
howev
except
occur
two
relev
passiv
immunotherapi
develop
diagnost
use
correspond
immunoglobulin
mention
three
class
hchain
gene
correspond
igm
igi
iga
exist
chicken
class
switch
occur
igm
either
igi
iga
igi
consid
ancestor
presentday
igg
ige
unlik
human
igg
igi
bind
cellular
fc
receptor
protein
g
respect
activ
complement
system
hchain
antibodi
devoid
light
chain
occur
camelida
speci
camel
dromedari
llama
singledomain
fragment
antibodi
react
specif
antigen
high
affin
constant
nanomolar
rang
bind
involv
longer
averag
third
variabl
loop
antibodi
molecul
uniqu
antibodi
antigenspecif
fragment
expect
becom
import
biotechnolog
medic
applic
includ
intrabodi
intracellular
antibodi
innat
immun
system
provid
earli
defens
pathogen
alert
adapt
immun
system
initi
invas
pathogen
occur
innat
system
predat
evolutionarili
adapt
system
reli
antimicrobi
peptid
germlineencod
patternrecognit
receptor
prr
antimicrobi
peptid
damag
envelop
virus
interfer
process
involv
fusion
virus
target
cell
membran
prr
recogn
microbi
viral
compon
defin
pathogenassoci
molecular
pattern
pamp
differ
prr
specif
distinct
pamp
distinct
express
pattern
activ
differ
signal
pathway
therebi
elicit
distinct
respons
invad
pathogen
prr
subdivid
two
class
tolllik
receptor
tlr
nontolllik
innat
immun
protein
toll
origin
identifi
differenti
protein
drosophila
later
shown
play
role
defens
fungal
infect
search
entir
dna
sequenc
databas
similar
code
sequenc
toll
result
identif
tolllik
sequenc
ultim
discoveri
least
function
tlr
human
tlr
type
integr
membran
glycoprotein
extracellular
domain
contain
sever
lrr
motif
cytoplasm
signal
domain
homolog
receptor
tlr
recogn
pamp
characterist
virus
viral
dna
rich
cpg
motif
recogn
lead
activ
proinflammatori
cytokin
type
interferon
ifn
secret
express
within
endosom
membran
specif
viral
singlestrand
rna
ssrna
doublestrand
rna
dsrna
gener
tlr
express
either
cell
surfac
lysosomalendosom
membran
therefor
would
recogn
pathogen
succeed
invad
cytosol
compart
pathogen
detect
varieti
cytoplasm
prr
includ
retino
acid
induc
protein
helicas
domain
recogn
viral
dsrna
relat
protein
protein
may
involv
innat
antivir
immun
includ
trigger
receptor
myeloid
cell
myeloid
ctype
lectin
siglec
recogn
sialic
acid
one
element
innat
adapt
immun
complement
system
virus
virusinfect
cell
directli
activ
complement
cascad
absenc
antivir
antibodi
mani
virus
endow
properti
subvert
innat
immun
respons
vaccinia
viru
produc
protein
suppress
tlrand
signal
cascad
paramyxovirus
produc
protein
associ
thu
inhibit
dsrnainduc
activ
process
adenovirus
avoid
immun
surveil
nonstructur
protein
hepat
c
viru
block
signal
marburg
ebola
virus
member
famili
filovirida
elicit
direct
activ
neutrophil
lead
vigor
inflammatori
respons
contribut
fatal
hemorrhag
fever
infect
human
thu
virus
develop
strategi
overcom
either
innat
adapt
see
next
section
immun
respons
adapt
immun
complex
anticipatori
system
trigger
exposur
antigen
includ
virus
hallmark
select
diversif
specif
memori
princip
effector
molecul
system
antigenbind
receptor
immunoglobulin
ig
tcell
receptor
tcr
follow
simplifi
overview
see
figur
limit
ig
humor
immun
respons
differenti
bcell
antibodygener
plasma
cell
occur
distinct
pathway
two
pathway
lead
rapid
igm
iga
antibodi
product
cell
tcellindepend
antigen
antibodi
low
antigenbind
constant
immunolog
memori
evolv
third
pathway
involv
clonal
select
bcell
synthes
igm
igd
low
affin
antibodi
express
antigen
receptor
surfac
cell
bcell
produc
differ
receptor
recogn
distinct
epitop
encount
appropri
epitop
antigen
elicit
cell
divis
gener
select
clone
ident
receptor
specif
clone
differenti
specif
antibodysecret
cell
remark
divers
antibodi
attribut
fact
gene
code
ig
variabl
region
inherit
set
gene
fragment
encod
portion
variabl
region
particular
ig
polypeptid
chain
fragment
join
togeth
form
complet
gene
individu
lymphocyt
join
process
involv
addit
dna
sequenc
end
fragment
join
thu
increas
divers
divers
aris
assembl
ig
protein
pair
hand
lchain
bcell
produc
one
kind
either
chain
figur
addit
assembl
gene
ig
mutat
rapidli
bcell
activ
bind
antigen
hypermut
lead
new
receptor
variant
repres
process
affin
matur
immun
respons
moreov
bcell
progeni
produc
addit
variat
alter
constant
part
h
chain
due
gene
rearrang
isotyp
subclass
switch
figur
antibodi
ident
paratop
distinct
effector
function
complement
activ
phagocytosi
transcytosi
etc
consequ
aforement
process
blymphocyt
least
million
distinct
specif
everi
human
individu
given
time
major
ig
produc
mucosaassoci
tissu
predominantli
intestin
rather
bone
marrow
spleen
lymph
node
form
iga
harmon
fact
mucos
surfac
repres
predomin
site
entri
pathogen
includ
virus
coincident
demonstr
gut
major
site
replic
deplet
cell
two
subclass
iga
occur
monomer
dimer
tetramer
polymer
piga
form
distinguish
featur
secretori
iga
associ
anoth
glycoprotein
secretori
compon
sc
figur
sc
also
extracellular
portion
gener
proteolyt
cleavag
integr
epitheli
cell
membran
protein
polymer
ig
receptor
pigr
mediat
transcytosi
piga
igm
latter
process
allow
neutral
pathogen
within
intracellular
vesicular
compart
essenti
aspect
adapt
immun
abil
recal
past
encount
pathogen
decad
even
entir
lifetim
fundament
featur
foundat
success
vaccin
germin
centerderiv
memori
bcell
follow
attribut
antigen
specif
hypermut
ig
variabl
gene
segment
abil
bestow
immunolog
memori
follow
adopt
transfer
immunolog
recipi
surfac
antigen
marker
memori
bcell
multifacet
perform
bcell
result
thoroughli
orchestr
ensembl
involv
helper
tcell
dc
mhc
class
ii
antigen
celldifferenti
antigen
cd
cytokin
etc
summari
addit
occup
ig
receptor
bcell
must
interact
antigenspecif
tcell
tcell
specif
tcr
recogn
peptid
fragment
gener
antigen
intern
bcell
display
surfac
bcell
peptidemhc
class
ii
complex
helper
tcell
stimul
bcell
follow
bind
ligand
tcell
bcell
interact
tumor
necrosi
factor
tnf
tnf
receptor
famili
ligand
pair
releas
specif
cytokin
detail
interact
shown
figur
intricaci
tightli
coordin
event
seem
minim
possibl
ration
design
synthet
vaccin
abl
success
recreat
specif
viru
neutral
bcell
epitop
neotop
surfac
virus
repres
mosaic
cluster
protein
glycoprotein
subunit
subunit
correspond
singl
two
speci
pattern
repetit
usual
key
factor
respons
effici
earli
rapid
bcell
respons
potent
igm
antibodi
product
effici
downstream
antibodi
class
switch
howev
immun
respons
restrict
antigen
site
epitop
neotop
surfac
virus
viru
particl
follow
initi
infect
provid
vaccin
also
separ
constitu
part
consequ
unassembl
surfac
subunit
epitop
cryptotop
intern
viru
compon
becom
expos
immun
system
ultim
result
product
antibodi
multipl
specif
direct
intact
virus
may
virusneutr
properti
format
antibodi
distinct
specif
may
simultan
rather
sequenti
especi
case
directli
cytopath
virus
hepat
b
c
lymphocyt
choriomening
prone
elicit
chronic
carrier
state
virusneutr
antibodi
vnab
appear
delay
nonneutr
antibodi
latter
may
function
decoy
target
like
vnab
viru
surfac
epitop
vnab
crucial
protect
reinfect
viru
vnab
specif
protect
efficaci
vaccin
correl
close
vitro
determin
vnab
titer
sera
immun
individu
protect
passiv
immun
reli
vnab
recogn
neutral
epitop
neotop
viru
surfac
coat
viru
particl
antibodi
necessari
alway
suffici
viru
neutral
effect
viru
neutral
correl
rate
antibodi
bind
critic
epitop
augment
slow
dissoci
form
antigenantibodi
complex
kinet
paramet
determin
experiment
spatial
adapt
complementar
electrostat
interact
hydrogen
bond
van
der
waal
forc
contribut
bind
experiment
determin
viru
neutral
depend
target
cell
use
viru
neutral
multihit
process
success
number
unencumb
viral
molecul
essenti
initi
viru
replic
cycl
brought
minimum
threshold
level
mechan
neutral
depend
process
obligatori
reproduct
particular
viru
may
involv
follow
step
attach
cell
receptor
postattach
event
intern
endocytosi
fusion
cell
membran
endosom
vesicl
uncoat
andor
intracellular
local
enzymat
activ
eg
transcript
direct
occup
vnab
cell
receptor
bind
site
viru
surfac
might
obligatori
neutral
steric
hindranc
induct
deleteri
conform
chang
may
suffici
effect
uniqu
featur
sever
human
monoclon
vnab
distinct
specif
long
fingerlik
third
complementar
determin
region
immunoglobulin
heavi
chain
allow
access
recess
critic
site
featur
rare
human
immunoglobulin
repertoir
common
ig
camelida
mechan
magnitud
vnab
neutral
effect
influenc
immunoglobulin
isotyp
subtyp
affect
interact
complement
fc
receptor
transcytosi
mucos
epithelia
nonneutr
virussurfacebind
antibodi
sometim
enhanc
effect
vnab
limit
viral
spread
earli
phase
infect
contribut
suppress
antibodymedi
cellular
cytotox
adcc
antibodi
direct
epitop
neotop
distinct
surfac
protein
may
act
synergist
viru
neutral
principl
vnab
specif
viru
surfac
compon
provid
protect
diseas
absolut
flaviviru
nonstructur
protein
elicit
protect
immun
respons
yellow
fever
dengu
tickborn
enceph
virus
paratop
bind
site
contain
f
ab
fragment
ineffect
thu
immunoglobulin
fc
portion
obligatori
protect
effect
virus
make
use
antivir
antibodi
gain
entri
target
cell
thu
widen
cell
receptor
usag
initi
infect
infecti
virusantibodi
complex
reli
upon
fc
portion
igg
antibodi
gain
entri
monocytesmacrophag
granulocyt
fc
fcr
complement
receptor
cr
express
cellsth
characterist
featur
virus
propens
establish
persist
infect
antigen
divers
antibodydepend
enhanc
ade
demonstr
occur
vitro
member
famili
bunyavirida
coronavirida
flavivirida
orthomyxovirida
paramyxovirida
retrovirida
rhabdovirida
togavirida
link
vitro
ade
clinic
manifest
alway
establish
relationship
ade
diseas
exacerb
observ
dengu
measl
yellow
fever
respiratori
syncyti
virus
rsv
ade
may
occur
children
infect
time
level
transfer
matern
antivir
antibodi
declin
insuffici
level
ade
could
repres
obstacl
develop
vaccin
case
antirsv
vaccin
vaccin
consist
formaldehydetr
measl
viru
hemagglutinin
ineffect
elicit
antibodi
viru
fusion
protein
induc
antibodi
caus
ade
led
aggrav
atyp
diseas
follow
infect
measl
viru
fcrand
crindepend
ade
shown
occur
follow
bind
antibodi
elicit
conform
chang
envelop
glycoprotein
allow
direct
viru
bind
cellular
coreceptor
bypass
primari
bind
primari
cell
receptor
persist
infect
host
repeat
reactiv
mani
virus
reli
sever
specif
evas
strategi
adapt
immun
thu
common
protect
respons
redirect
alter
advantag
infecti
agent
includ
antivir
antibodi
respons
involv
specif
paratopeepitop
interact
fab
fragment
effector
mechan
mediat
fc
portion
antibodi
first
mechan
provid
genet
determin
amino
acid
replac
lead
chang
viru
epitop
neotop
involv
viru
neutral
site
escap
mutat
usual
viral
surfac
result
structur
chang
antibodi
viru
contact
site
lead
much
less
favor
kinet
paramet
antibodi
bind
complet
abrog
bind
present
new
glycan
chain
envelop
virus
elimin
chain
due
mutat
nglycosyl
site
may
caus
substanti
epitop
alter
rate
escap
mutat
appear
promot
errorpron
replic
viral
genom
antibodi
new
specif
must
produc
bring
mutant
virus
control
process
repeat
success
persist
infect
establish
similar
process
lead
evas
tcellmedi
protect
respons
secondli
sever
virus
bypass
clearanc
process
facilit
fc
portion
bound
antibodi
encod
express
fc
receptor
analog
subvers
complement
cascad
provid
anoth
way
block
clearanc
cellfre
viru
infect
cell
addit
scenario
escap
immun
surveil
includ
interfer
mhc
class
restrict
antigen
present
involv
also
inhibit
mhc
class
cell
surfac
express
synthesi
viral
mhc
class
homolog
block
mhc
class
ii
restrict
antigen
present
downregul
cellular
degrad
interfer
cytokin
effector
function
strategi
transfer
immun
immun
donor
unprotect
recipi
serum
one
earli
landmark
histori
immunolog
von
behr
activ
serum
compon
later
identifi
immunoglobulin
halflif
immunoglobulin
isotyp
serum
day
figur
consequ
administ
antiviru
immunoglobulin
provid
short
term
prophylact
therapeut
benefit
respect
unless
administ
repeatedli
incorpor
slowreleas
medic
devic
common
applic
preexposur
travel
protect
communitywid
infect
medic
profession
immunosuppress
individu
combin
live
vaccin
minim
potenti
side
effect
postexposur
prophylaxi
passiv
immun
may
provid
immedi
protect
benefit
vaccin
delay
local
mucos
applic
immunoglobulin
need
appear
promis
perinat
sexual
transmiss
respect
sever
virus
eg
herpesvirus
immunoglobulin
isol
serum
individu
prescreen
high
level
antibodi
particular
viru
vaccin
individu
immunoglobulin
purifi
treat
remov
inactiv
infecti
agent
might
present
pool
serum
sourc
notwithstand
rigor
screen
individu
sera
enter
pool
product
process
depend
intend
intramuscular
intraven
applic
immunoglobulin
polyclon
respect
indic
viru
contain
antibodi
origin
present
pool
sera
oral
administr
antibodi
produc
bovin
colostrum
chicken
yolk
recent
suggest
altern
monoclon
antibodi
mab
specif
epitop
known
elicit
virusneutr
protect
immun
respons
use
prepar
use
hybridoma
technolog
immort
human
peripher
bcell
transgen
mice
bacteriophag
express
librari
deriv
anim
speci
mab
human
use
recombin
dna
techniqu
replac
amino
acid
sequenc
outsid
antigenbind
site
sequenc
correspond
human
immunoglobulin
vitro
direct
evolut
process
allow
manipul
antigenbind
kinet
mab
variant
much
faster
antigen
associ
rate
much
slower
dissoci
rate
produc
antibodi
much
improv
capac
neutral
target
viru
may
great
clinic
potenti
product
high
yield
plant
offer
econom
advantag
approach
applic
igg
secretori
iga
antibodi
polyclon
antibodi
human
sera
provid
immunolog
divers
mab
highli
specif
singl
viru
epitop
potenti
alter
epitop
may
gener
viru
neutral
escap
mutant
decreas
elimin
effect
mab
prophylacticstherapeut
polyclon
antibodi
prepar
prepar
pool
sera
uniform
vari
sourc
serum
pool
problem
overcom
develop
human
recombin
antigenspecif
polyclon
antibodi
novel
sympress
technolog
symphogen
lyngbi
denmark
immunoglobulin
either
alreadi
clinic
use
develop
direct
one
follow
virus
hepat
b
cytomegaloviru
rabi
respiratori
syncyti
viru
smallpox
vaccinia
varicella
zoster
measl
mump
rubella
parvoviru
epsteinbarr
viru
herp
simplex
tickborn
enceph
polioviru
hantaviru
west
nile
viru
rotaviru
polioviru
ebola
viru
sever
acut
respiratori
syndromeassoci
coronaviru
unlik
vaccin
passiv
immun
rapidli
deliv
protect
level
antibodi
directli
suscept
mucos
site
mani
viru
infect
initi
secretori
iga
polyval
rel
stabil
may
advantag
igg
passiv
immun
site
antibodi
function
also
immunomodul
bridg
innat
acquir
cellular
humor
immun
respons
respect
infect
host
cell
target
link
anticellular
toxin
antivir
antibodi
bispecif
antibodi
one
fab
fragment
antibodi
viru
specif
one
recogn
host
cell
compon
receptor
research
antibodymedi
immun
understand
antibodybas
prophylaxi
therapi
viru
diseas
provid
foundat
research
develop
antiviru
vaccin
vaccin
success
medic
intervent
viral
diseas
vaccin
prevent
moder
ill
caus
viru
infect
individu
prevent
diminish
viru
transmiss
suscept
person
thu
contribut
herd
immun
effect
expect
long
term
depend
establish
immunolog
memori
band
tcell
level
may
requir
consecut
repeat
vaccin
effect
vaccin
might
diminish
compromis
virus
occur
form
simultan
quasispeci
undergo
timedepend
chang
antigen
properti
antigen
drift
antigen
shift
howev
case
vaccin
predispos
aggrav
diseas
elicit
infect
viru
ident
relat
use
vaccin
antibodi
enhanc
viru
infect
occur
dengu
respiratori
syncyti
virus
follow
categori
vaccin
distinguish
tabl
live
attenu
whole
viru
inactiv
glycoprotein
subunit
vaccin
protein
vaccin
base
recombin
dna
technolog
one
vaccin
categori
hepat
b
surfac
antigen
hbsag
deriv
plasma
hepat
b
viru
carrier
remark
vaccin
categori
correspond
multisubunit
selfassembl
particl
antigen
specif
close
similar
ident
express
surfac
viru
particl
hand
individu
viru
protein
glycoprotein
subunit
molecul
peptid
fragment
less
suitabl
candid
vaccin
develop
insuffici
similar
intact
virus
vaccin
formul
requir
incorpor
immunolog
adjuv
enhanc
immunogen
adjuv
design
optim
antigen
deliveri
present
enhanc
matur
antigenpres
dendrit
cell
induc
immunomodulatori
cytokin
current
vaccin
administ
parenter
use
syring
needlesth
procedur
dislik
mani
question
mass
vaccin
program
develop
countri
therefor
effort
made
produc
vaccin
deliv
onto
mucos
surfac
mostli
oral
nasal
addit
highworkload
needlefre
inject
devic
develop
junctur
bifurc
needl
develop
benjamin
rubin
year
ago
must
mention
prove
essenti
success
campaign
erad
smallpox
worldwid
develop
use
veterinari
vaccin
follow
aim
costeffect
prevent
control
viru
diseas
anim
induc
herd
immun
improv
anim
welfar
food
product
human
consumpt
decreas
usag
veterinari
drug
therebi
minim
environment
impact
food
contamin
decreas
incid
zoonos
eg
infect
avian
influenza
rabi
west
nile
rift
valley
fever
virus
respect
research
develop
product
veterinari
vaccin
forefront
gener
field
vaccinolog
footandmouth
diseas
viru
vaccin
first
one
produc
industri
scale
frenkel
method
vacciniarabi
viru
g
protein
recombin
vaccin
among
first
biotechnologybas
vaccin
licens
world
first
dna
vaccin
west
nile
viru
hors
approv
us
depart
agricultur
juli
diva
differenti
infect
vaccin
anim
also
term
marker
veterinari
recombin
vaccin
companion
diagnost
test
develop
appli
program
control
erad
viru
infect
exampl
consid
develop
human
vaccin
latter
requir
rigor
evalu
safeti
efficaci
difficult
obtain
veterinari
set
list
licens
veterinari
vaccin
shown
tabl
